Additional Relevant Details "Roche plans to pursue marketing authorization for both PPMS and relapsing multiple sclerosis (RMS), a more common form of the disease, and will submit data from three pivotal Phase III studies to global regulatory authorities in the first half of 2016."  The drug, Ocrelizumab, is a breakthrough therapy drug designed to treat both PPMS and RMS.